News | Holter Monitoring Systems | September 27, 2016

BioTelemetry Inc. Announces CE Mark Approval of Holter Analysis Software

Software can be used stand-alone or with BioTelemetry’s digital Holter recorders

BioTelemetry, CE Mark, Holter analysis software

September 27, 2016 — BioTelemetry Inc. announced in late August that the company has received CE mark approval of its Holter analysis software. The software can be used either on a stand-alone basis or in combination with the company’s family of digital Holter recorders.

BioTelemetry President and CEO Joseph H. Capper said the company expects to launch an integrated solution with the newly acquired ePatch device (acquired from Delta Danish Electronics, Light & Acoustics in April) in the near future. The Holter software currently operates with BioTelemetry’s legacy Holter recorders.

The company expects to market the Holter analysis software under the Millennia brand name.

For more information: www.gobio.com

Related Content

News | Cardiac Diagnostics | May 23, 2019

Late Dinner and No Breakfast Worsens Outcomes After Heart Attack

People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...

News | Cardiac Diagnostics | May 14, 2019

HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy

The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...

News | Cardiac Diagnostics | April 15, 2019

New Best Practices Help Manage Heart Attack Patients Without Significant Signs

For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...

Videos | Cardiac Diagnostics | March 26, 2019

VIDEO: Use of Plant-Based Diet to Reduce Cardiovascular Disease Risk

...

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.

Advantages of High Sensitivity Troponin Assays

Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract

Feature | Cardiac Diagnostics | March 18, 2019

ACC/AHA Update Guidance for Preventing Heart Disease, Stroke

The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...

News | Cardiac Diagnostics | March 08, 2019

AHA Statement Warns Hookah Smoking May Harm the Heart

Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...

News | Cardiac Diagnostics | February 20, 2019

PTSD Alone Does Not Increase Heart Disease Risk in Veterans

February 20, 2019 — Post-traumatic stress disorder (PTSD) by itself does not explain the...

News | Cardiac Diagnostics | February 18, 2019

Hormone Therapy May Increase Cardiovascular Risk During Gender Transition

Patients receiving hormone therapy as part of their gender-transition treatment had an elevated risk for cardiovascular...

News | Cardiac Diagnostics | February 15, 2019

IBM and Broad Institute Launch AI Initiative for Cardiovascular Disease Risk Prediction

IBM Watson Health and the Broad Institute of MIT and Harvard are launching a research partnership aimed at developing...